Symbols / RAPT $58.02 +0.00%
RAPT Chart
About
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. RAPT Therapeutics, Inc. is a subsidiary of Bristol-Myers Squibb Company.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.68B |
| Enterprise Value | 1.45B | Income | -105.64M | Sales | — |
| Book/sh | 9.02 | Cash/sh | 5.68 | Dividend Yield | — |
| Payout | 0.00% | Employees | 60 | IPO | Oct 31, 2019 |
| P/E | — | Forward P/E | -21.38 | PEG | — |
| P/S | — | P/B | 6.43 | P/C | — |
| EV/EBITDA | -13.01 | EV/Sales | — | Quick Ratio | 11.76 |
| Current Ratio | 12.04 | Debt/Eq | 1.71 | LT Debt/Eq | — |
| EPS (ttm) | -11.66 | EPS next Y | -2.71 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-05 | ROA | -51.35% |
| ROE | -85.37% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 28.96M |
| Shs Float | 16.85M | Short Float | 8.59% | Short Ratio | 0.42 |
| Short Interest | — | 52W High | 58.02 | 52W Low | 5.67 |
| Beta | 0.44 | Avg Volume | 2.40M | Volume | 10.85M |
| Target Price | $58.00 | Recom | Hold | Prev Close | $58.02 |
| Price | $58.02 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$58.00
Mean price target
2. Current target
$58.02
Latest analyst target
3. DCF / Fair value
$-28.83
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$58.02
Low
$58.00
High
$58.00
Mean
$58.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-21 | down | Barclays | Overweight → Equal-Weight | $58 |
| 2026-01-21 | down | Leerink Partners | Outperform → Market Perform | $58 |
| 2026-01-20 | down | Wells Fargo | Overweight → Equal-Weight | $58 |
| 2026-01-20 | down | LifeSci Capital | Outperform → Market Perform | — |
| 2026-01-20 | down | TD Cowen | Buy → Hold | — |
| 2026-01-20 | down | HC Wainwright & Co. | Buy → Neutral | $58 |
| 2026-01-20 | down | Clear Street | Buy → Hold | $58 |
| 2025-12-18 | init | TD Cowen | — → Buy | — |
| 2025-11-12 | main | JP Morgan | Overweight → Overweight | $57 |
| 2025-11-07 | main | Barclays | Overweight → Overweight | $56 |
| 2025-11-03 | main | Wells Fargo | Overweight → Overweight | $72 |
| 2025-10-27 | main | HC Wainwright & Co. | Buy → Buy | $72 |
| 2025-10-27 | init | Guggenheim | — → Buy | $70 |
| 2025-10-21 | main | Wells Fargo | Overweight → Overweight | $48 |
| 2025-10-21 | main | Barclays | Overweight → Overweight | $58 |
| 2025-10-21 | main | Clear Street | Buy → Buy | $60 |
| 2025-10-20 | up | JP Morgan | Neutral → Overweight | $55 |
| 2025-10-13 | init | Barclays | — → Overweight | $35 |
| 2025-09-30 | main | Clear Street | Buy → Buy | $41 |
| 2025-09-26 | up | Leerink Partners | Market Perform → Outperform | $37 |
- Assessing RAPT Therapeutics (RAPT) Valuation After A Sharp 3 Month Share Price Surge - Yahoo Finance Sat, 28 Feb 2026 08
- This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share - The Globe and Mail Sun, 15 Mar 2026 22
- Why Rapt Therapeutics Stock Soared Today - The Motley Fool ue, 20 Jan 2026 08
- Rapt Therapeutics (NASDAQ:RAPT) Stock Rating Upgraded by Wall Street Zen - MarketBeat Sat, 07 Mar 2026 08
- GSK Digs In On Allergies With $2.2 Billion Rapt Therapeutics Buyout - Investor's Business Daily ue, 20 Jan 2026 08
- GSK to buy RAPT Therapeutics, maker of food allergy treatment, in $2.2B deal - statnews.com ue, 20 Jan 2026 08
- RAPT stock RAPT Therapeutics (NASDAQ) at $58.02 intraday 04 Mar 2026: earnings catalyst ahead - Meyka Wed, 04 Mar 2026 08
- RAPT Therapeutics (RAPT) director equity cashed out in $58-per-share GSK buyout - Stock Titan hu, 05 Mar 2026 14
- This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up. - Barron's ue, 20 Jan 2026 08
- Biggest stock movers Tuesday: NVDA, RAPT, MMM and more - Seeking Alpha ue, 20 Jan 2026 08
- Assessing RAPT Therapeutics (RAPT) Valuation After A Sharp Share Price Surge - Yahoo Finance Fri, 23 Jan 2026 08
- GSK acquisition cashes out RAPT (RAPT) CFO shares and options - Stock Titan hu, 05 Mar 2026 13
- GSK makes $2.2 billion swoop for RAPT Therapeutics' food allergy drug - Yahoo Finance ue, 20 Jan 2026 08
- RAPT Therapeutics (RAPT) director exits options and shares in GSK deal - Stock Titan hu, 05 Mar 2026 13
- [EFFECT] RAPT Therapeutics, Inc. SEC Filing - Stock Titan hu, 05 Mar 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4956 | — | — | Stock Award(Grant) at price 0.00 per share. | GRAY MARY ANN | Director | — | 2026-01-30 00:00:00 | D |
| 1 | 4956 | — | — | Stock Award(Grant) at price 0.00 per share. | DOMBKOWSKI ASHLEY L | Director | — | 2026-01-30 00:00:00 | D |
| 2 | 4956 | — | — | Stock Award(Grant) at price 0.00 per share. | BRAUNSTEIN SCOTT N. | Director | — | 2026-01-30 00:00:00 | D |
| 3 | 4956 | — | — | Stock Award(Grant) at price 0.00 per share. | LYONS-WILLIAMS LORI | Director | — | 2026-01-30 00:00:00 | D |
| 4 | 4956 | — | — | Stock Award(Grant) at price 0.00 per share. | GIORDANO MICHAEL F | Director | — | 2026-01-30 00:00:00 | D |
| 5 | 4956 | — | — | Stock Award(Grant) at price 0.00 per share. | KOZICK LINDA | Director | — | 2026-01-30 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -134.90M | -125.85M | -84.75M | -68.21M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -129.87M | -116.80M | -83.84M | -69.20M |
| ReconciledDepreciation | 1.20M | 1.22M | 1.05M | 996.00K |
| EBITDA | -134.90M | -125.85M | -84.75M | -68.21M |
| EBIT | -136.10M | -127.06M | -85.80M | -69.21M |
| NormalizedIncome | -129.87M | -116.80M | -83.84M | -69.20M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -129.87M | -116.80M | -83.84M | -69.20M |
| TotalExpenses | 136.10M | 127.06M | 87.32M | 73.02M |
| TotalOperatingIncomeAsReported | -136.10M | -127.06M | -85.80M | -69.21M |
| DilutedAverageShares | 5.10M | 4.79M | 4.07M | 3.42M |
| BasicAverageShares | 5.10M | 4.79M | 4.07M | 3.42M |
| DilutedEPS | -25.52 | -24.40 | -20.64 | -20.24 |
| BasicEPS | -25.52 | -24.40 | -20.64 | -20.24 |
| DilutedNIAvailtoComStockholders | -129.87M | -116.80M | -83.84M | -69.20M |
| NetIncomeCommonStockholders | -129.87M | -116.80M | -83.84M | -69.20M |
| NetIncome | -129.87M | -116.80M | -83.84M | -69.20M |
| NetIncomeIncludingNoncontrollingInterests | -129.87M | -116.80M | -83.84M | -69.20M |
| NetIncomeContinuousOperations | -129.87M | -116.80M | -83.84M | -69.20M |
| TaxProvision | 0.00 | |||
| PretaxIncome | -129.87M | -116.80M | -83.84M | -69.20M |
| OtherIncomeExpense | 6.24M | 10.26M | 1.96M | 5.00K |
| OtherNonOperatingIncomeExpenses | 6.24M | 10.26M | 1.96M | 5.00K |
| OperatingIncome | -136.10M | -127.06M | -85.80M | -69.21M |
| OperatingExpense | 136.10M | 127.06M | 87.32M | 73.02M |
| ResearchAndDevelopment | 107.22M | 101.00M | 67.08M | 56.98M |
| SellingGeneralAndAdministration | 28.88M | 26.06M | 20.24M | 16.04M |
| GeneralAndAdministrativeExpense | 28.88M | 26.06M | 20.24M | 16.04M |
| OtherGandA | 28.88M | 26.06M | 20.24M | 16.04M |
| TotalRevenue | 0.00 | 0.00 | 1.53M | 3.81M |
| OperatingRevenue | 0.00 | 0.00 | 1.53M | 3.81M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 16.50M | 4.30M | 4.28M | 3.69M |
| ShareIssued | 16.50M | 4.30M | 4.28M | 3.69M |
| TotalDebt | 4.49M | 6.91M | 8.99M | 0.00 |
| TangibleBookValue | 189.90M | 147.03M | 245.17M | 186.38M |
| InvestedCapital | 189.90M | 147.03M | 245.17M | 186.38M |
| WorkingCapital | 186.88M | 139.95M | 238.47M | 183.38M |
| NetTangibleAssets | 189.90M | 147.03M | 245.17M | 186.38M |
| CapitalLeaseObligations | 4.49M | 6.91M | 8.99M | 0.00 |
| CommonStockEquity | 189.90M | 147.03M | 245.17M | 186.38M |
| TotalCapitalization | 189.90M | 147.03M | 245.17M | 186.38M |
| TotalEquityGrossMinorityInterest | 189.90M | 147.03M | 245.17M | 186.38M |
| StockholdersEquity | 189.90M | 147.03M | 245.17M | 186.38M |
| GainsLossesNotAffectingRetainedEarnings | 50.00K | 103.00K | -26.00K | -206.00K |
| OtherEquityAdjustments | 50.00K | 103.00K | -26.00K | -206.00K |
| RetainedEarnings | -614.55M | -484.68M | -367.88M | -284.05M |
| AdditionalPaidInCapital | 804.39M | 631.61M | 613.07M | 470.63M |
| CapitalStock | 13.00K | 3.00K | 3.00K | 3.00K |
| CommonStock | 13.00K | 3.00K | 3.00K | 3.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 50.42M | 26.29M | 21.04M | 12.26M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.07M | 4.46M | 6.82M | 2.66M |
| NonCurrentDeferredLiabilities | 0.00 | 2.66M | ||
| NonCurrentDeferredRevenue | 0.00 | 511.00K | ||
| LongTermDebtAndCapitalLeaseObligation | 2.07M | 4.46M | 6.82M | 0.00 |
| LongTermCapitalLeaseObligation | 2.07M | 4.46M | 6.82M | 0.00 |
| CurrentLiabilities | 48.35M | 21.84M | 14.22M | 9.60M |
| OtherCurrentLiabilities | 57.00K | 109.00K | 32.00K | 254.00K |
| CurrentDeferredLiabilities | 0.00 | 1.02M | ||
| CurrentDeferredRevenue | 0.00 | 1.02M | ||
| CurrentDebtAndCapitalLeaseObligation | 2.42M | 2.45M | 2.17M | |
| CurrentCapitalLeaseObligation | 2.42M | 2.45M | 2.17M | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 6.72M | 6.30M | 4.62M | 3.65M |
| PayablesAndAccruedExpenses | 39.15M | 12.98M | 7.40M | 4.67M |
| CurrentAccruedExpenses | 2.87M | 7.80M | 4.04M | 2.67M |
| Payables | 36.27M | 5.18M | 3.37M | 2.00M |
| OtherPayable | 35.00M | |||
| AccountsPayable | 1.27M | 5.18M | 3.37M | 2.00M |
| TotalAssets | 240.32M | 173.33M | 266.21M | 198.64M |
| TotalNonCurrentAssets | 5.09M | 11.55M | 13.52M | 5.66M |
| OtherNonCurrentAssets | 389.00K | 3.87M | 4.04M | 2.92M |
| NetPPE | 4.70M | 7.68M | 9.48M | 2.74M |
| AccumulatedDepreciation | -10.08M | -9.37M | -8.25M | -7.68M |
| GrossPPE | 14.78M | 17.04M | 17.73M | 10.43M |
| Leases | 3.29M | 3.29M | 3.29M | 3.29M |
| OtherProperties | 10.37M | 12.63M | 13.50M | 6.29M |
| MachineryFurnitureEquipment | 1.12M | 1.12M | 935.00K | 839.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 235.24M | 161.78M | 252.69M | 192.97M |
| OtherCurrentAssets | 4.18M | 2.92M | 3.63M | 3.32M |
| PrepaidAssets | 3.32M | |||
| CashCashEquivalentsAndShortTermInvestments | 231.06M | 158.86M | 249.07M | 189.65M |
| OtherShortTermInvestments | 61.32M | 111.38M | 210.12M | 165.63M |
| CashAndCashEquivalents | 169.74M | 47.48M | 38.95M | 24.03M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -83.42M | -98.17M | -71.62M | -61.78M |
| IssuanceOfCapitalStock | 152.01M | 0.00 | 129.79M | 139.46M |
| CapitalExpenditure | -122.00K | -1.12M | -845.00K | -755.00K |
| IncomeTaxPaidSupplementalData | 0.00 | |||
| EndCashPosition | 169.74M | 47.48M | 38.95M | 24.03M |
| BeginningCashPosition | 47.48M | 38.95M | 24.03M | 24.92M |
| ChangesInCash | 122.26M | 8.53M | 14.92M | -891.00K |
| FinancingCashFlow | 152.85M | 1.45M | 131.18M | 141.48M |
| CashFlowFromContinuingFinancingActivities | 152.85M | 1.45M | 131.18M | 141.48M |
| ProceedsFromStockOptionExercised | 845.00K | 1.45M | 1.39M | 2.02M |
| NetCommonStockIssuance | 152.01M | 0.00 | 129.79M | 139.46M |
| CommonStockIssuance | 152.01M | 0.00 | 129.79M | 139.46M |
| InvestingCashFlow | 52.70M | 104.13M | -45.49M | -81.35M |
| CashFlowFromContinuingInvestingActivities | 52.70M | 104.13M | -45.49M | -81.35M |
| NetInvestmentPurchaseAndSale | 52.82M | 105.26M | -44.65M | -80.59M |
| SaleOfInvestment | 135.04M | 266.75M | 146.21M | 84.39M |
| PurchaseOfInvestment | -82.22M | -161.50M | -190.86M | -164.98M |
| NetPPEPurchaseAndSale | -122.00K | -1.12M | -845.00K | -755.00K |
| SaleOfPPE | 0.00 | 0.00 | ||
| PurchaseOfPPE | -122.00K | -1.12M | -845.00K | -755.00K |
| OperatingCashFlow | -83.30M | -97.05M | -70.77M | -61.03M |
| CashFlowFromContinuingOperatingActivities | -83.30M | -97.05M | -70.77M | -61.03M |
| ChangeInWorkingCapital | 25.91M | 5.50M | -1.33M | -4.30M |
| ChangeInOtherWorkingCapital | -1.53M | -3.47M | ||
| ChangeInOtherCurrentLiabilities | -2.85M | -2.71M | -2.10M | 0.00 |
| ChangeInPayablesAndAccruedExpense | 26.54M | 7.33M | 3.71M | 933.00K |
| ChangeInPayable | 26.54M | 7.33M | 3.71M | 933.00K |
| ChangeInAccountPayable | -8.46M | 7.33M | 3.71M | 933.00K |
| ChangeInPrepaidAssets | 2.22M | 871.00K | -1.42M | -1.76M |
| OtherNonCashItems | 2.34M | 2.33M | 1.76M | |
| StockBasedCompensation | 19.93M | 17.09M | 11.26M | 9.95M |
| AmortizationOfSecurities | -2.81M | -5.74M | -296.00K | 1.27M |
| DepreciationAmortizationDepletion | 1.20M | 1.22M | 1.05M | 996.00K |
| DepreciationAndAmortization | 1.20M | 1.22M | 1.05M | 996.00K |
| OperatingGainsLosses | -655.00K | 627.00K | 258.00K | |
| NetForeignCurrencyExchangeGainLoss | 0.00 | -655.00K | 627.00K | 258.00K |
| GainLossOnSaleOfPPE | 0.00 | |||
| NetIncomeFromContinuingOperations | -129.87M | -116.80M | -83.84M | -69.20M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for RAPT
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|